Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q3 2020 · 10-Q
Revenue$1.46M$1.46M−83.8% vs Q3 2019 Net Income-$6.79M-$6.79MN/M vs Q3 2019 EPS Diluted-$2.10-$2.10N/M vs Q3 2019 Operating Income-$6,246,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-426.9%−299.8 pt vs Q3 2019
Net margin-464.2%−387.3 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 10, 2020 · 41 d after period end